Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... June 19, 2019 , ... ... in vitro toxicology testing solutions, announced the addition of the Human MDR-1 ... existing in vitro toxicology offerings and allows researchers to perform critical toxicology testing ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... new facilities at 11500 W Olympic Blvd Suite 350 Los Angeles, CA, 90064, ... through research-backed methodologies. , MY Education Guru has created individual programs to ...
(Date:6/18/2019)... Tenn. (PRWEB) , ... June 18, 2019 , ... ... leader in emergency medicine and hospital medicine management services, are pleased to announce ... company based in Longview, Texas. , LEMA’s 34 physicians and 9 advanced ...
Breaking Medicine Technology:
(Date:6/19/2019)... ... ... CEO Steven C. Bilt of Smile Brands Inc. has won a Glassdoor Employees’ ... one of the world’s largest job and recruiting sites, released its annual report recognizing ... North America and parts of Europe. , Smile Brands, a leading dental support organization ...
(Date:6/19/2019)... ... June 19, 2019 , ... LifeLearn Animal Health launches ... pet insurance is, what it isn’t, and the questions they need to ask prior ... from different pet insurance companies and find the coverage that meets their budget and ...
(Date:6/18/2019)... ... June 18, 2019 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Aaron Berger, MD, Associated Urological Specialists, LLC in Chicago ... that Dr. Aaron Berger has achieved a high level of training and experience ...
(Date:6/16/2019)... ... June 16, 2019 , ... Ted Danson on CNBC ... research for the advancement of medical marijuana-based pharmaceuticals in an upcoming episode, scheduled ... more information. , With two investigational new drug applications already accepted by the ...
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, ... signed a memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis ... , MMJ BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana ...
Breaking Medicine News(10 mins):